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Introduction: Multiple studies have documented immune activation in many individuals with schizophrenia
suggesting that antigens capable of generating a prolonged immune response may be important environmental
factors inmany cases of this disorder.While existing studies have found single-agent associations of antibodies to
food and neurotropic infectious agents with schizophrenia, a simultaneous examination of multiple agents may
shed light on agent interactions or possible etiopathogenic pathways.
Methods: We used traditional regression and novel statistical techniques to examine associations of single and
combined infectious and food antigens with schizophrenia. We tested 6106 serum samples from 855 cases and
1165 matched controls.
Results: Higher antibody levels to casein were borderline significant in the prediction of schizophrenia
(HR= 1.08, p = 0.06). Study participantswith higher cytomegalovirus (CMV) IgG antibody levels had a reduced
risk of developing schizophrenia (HR= 0.90; p = 0.02). While IgG antibodies to gliadin, Toxoplasma gondii,
vaccinia, measles, and human herpesvirus-6 (HHV-6) showed no significant independent associations with
schizophrenia, the increase in antibody levels to several combinations of agents, to include casein, measles,
CMV, T. gondii and vaccinia, was predictive of an 18–34% increase in the risk of developing schizophrenia.
Conclusion: Certain patterns of antibodies, involving some agents, were predictive of developing schizophrenia,
with themagnitude of association rising when the level of antibodies increased to two or more agents. A height-
ened antibody response to a combination of several infectious/food antigens might be an indicator of an altered
immune response to antigenic stimuli.
Published by Elsevier B.V.
1. Introduction
Schizophrenia is a pervasive neuropsychiatric disorder with uncer-
tain etiology and pathogenesis, variable clinical presentations and out-
comes. The etiology of schizophrenia is complex and is likely to involve
both genetic and environmental components, which are very challeng-
ing to disentangle (O'Donovan et al., 2003; Maki et al., 2005; Tandon
et al., 2008). Multiple studies have documented immune activation in
many individuals with schizophrenia, suggesting that antigens capable
of generating a prolonged immune responsemay be important environ-
mental factors in this disorder (Moscavitch et al., 2009). These antigens
are likely to interactwith human leukocyte antigens (HLA) and theprod-
ucts of other immune response genes that have recently been found
to increase the risk of schizophrenia in several different populations
(Carter, 2009; Stefansson et al., 2009).
Existing studies examining single-agent associations of antibodies to
food and neurotropic infectious agents with schizophrenia have yielded
noteworthy but modest associations (Leweke et al., 2004; Yolken,
2004; Wang et al., 2006; Niebuhr et al., 2008a, 2008b; Dickerson et al.,
2010a; Severance et al., 2010;Niebuhr et al., 2011; Jin et al., 2012). Prob-
lems analyzing single-agent associations are compounded by the het-
erogeneity of IgG levels depending on the temporal proximity of the
specimen collection to the onset of schizophrenia and subjects' demo-
graphic characteristics. One limitation in the analysis of environmental
factors in a complex disorder such as schizophrenia is the lack of
existing statistical techniques to evaluate the possible direct or indirect
involvement of multiple environmental agents at different time points
before and after symptom onset.
The use of regression techniques withmultiple biomarkers is partic-
ularly difficult when the sample size is limited. Stepwise regression is
a well-known method for dimension reduction that is widely applied
and available in most commonly used statistical software packages.
One of the major limitations of this algorithm is its inability to address
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multicollinearity. In practice, multiple independent variables used in a
regression may have a high degree of correlation, making it difficult, if
not impossible, to distinguish the effect of each agent on the dependant
variable. As a result, the estimation and the test of statistical significance
becomeunreliable due to a violation of the assumption of independence
required for these tests. In the past several decades, a small number of
regression methods that adopt regularization have been introduced:
ridge regression (Hastie et al., 2001), subset selection, and principle
component analysis. Recently, there has been an increasing interest
in replacing the sample covariance with some sparse estimates of the
true covariance or its inverse for high-dimensional regression problems
(Witten and Tibshirani, 2009). Li and Niebuhr (2011) have recently
developed a gradient noise orthogonal (GNO)method based on finding
themost significant linear combination of the biomarkers in order to re-
duce the dimension.
We used traditional regression and novel GNO statistical techniques
(Li and Niebuhr, 2011) to examine associations of single and combined
infectious and food antigenswith schizophrenia. Based on the biological
plausibility and previously reported associations, four neurotropic
viruses [cytomegalovirus (CMV), human herpesvirus 6 (HHV-6), mea-
sles virus, and vaccinia virus], an apicomplexan protozoa (Toxoplasma
gondii) and two food antigens (casein and gliadin) were selected for
this study (Albrecht et al., 1980; Leweke et al., 2004; Yolken, 2004;
Wang et al., 2006; Dickerson et al., 2010a; Prasad et al., 2011; Jin et al.,
2012; Severance et al., 2012).
2. Methods
2.1. Data collection
Data for US military service members who received medical dis-
charges from the military with a diagnosis of schizophrenia from 1992
to 2005 were obtained from the US Army Physical Disability Agency,
the Secretary of the Navy Council of Review Boards, and the Air Force
Personnel Center/US Air Force Physical Disability Division. The rest of
the data were obtained using the Defense Medical Surveillance System
(DMSS). The diagnostic process leading to medical discharge from
military service and validity of the psychiatric diagnosis has been de-
tailed elsewhere (Millikan et al., 2007; Niebuhr et al., 2008a).
Those aged 18 and olderwhowere on active duty at the time of their
schizophrenia diagnosis and who had at least one serum sample of
0.5 ml or greater in the Department of Defense Serum Repository
(DoDSR) obtained prior to diagnosis were selected as potential study
cases. Hospitalized cases were preferentially selected so virtually all
(99%) study subjects were hospitalized with a psychiatric disorder
before their discharge from military service. The time of onset was
estimated as the earliest date of either the first hospitalizationwith psy-
chiatric disorder International Classification of Disease 9th Revision
(ICD-9-CM) codes (290–319) or the date themedical or physical evalu-
ation boards were initiated.
Control subjects, who were over the age of 18 with no inpatient or
outpatient psychiatric disorder diagnoses, were selected from the active
duty US military service population. One control per case was selected
for 700 males. To increase statistical power for comparison among fe-
males in a predominantlymale population, three controls were selected
for each of the 155 female cases. All control subjects were matched
to their cases on sex, race, branch of military service, date of birth
(+/−12months), military entrance (+/−12 months), and serum
specimen collection time (+/−90 days). Serum specimens, stored at
−30 °F, were obtained from the DoDSR. At least one, and up to four,
matched (+/−90 days) specimens were selected for each study sub-
ject. The enzyme-linked immunosorbent assay (ELISA) was used to
measure antibody levels to T. gondii, CMV, HHV-6, vaccinia andmeasles,
as well as to the food antigens casein and gliadin using previously de-
scribed methods. This study was approved by the Walter Reed Army
Institute of Research Institutional Review Board and the Institutional
Review Board of the Johns Hopkins School of Medicine.
3. Statistical analyses
The samples from each case–control group were analyzed on the
same microplate making within group comparisons more valid. In
order to control any systematic bias between plates, all agent measure-
ments were normalized. Robust random effect normalization consider-
ing both standard errors between and within plates was performed. To
minimize the differences in the ranges of antibody levels to the exam-
ined agents, their values were transformed into normal Z scores. The
standard deviation was chosen as a unit of measurement for antibody
levels.
To study the relationship betweenmultiple agent levels and the risk
of schizophrenia at different time points before and after its clinical
presentation, we grouped all specimens into several time periods. For
controls, the date of “diagnosis” was assigned from its matched case
keeping the serum collection order (i.e., the first serum sample of con-
trols was matched with the first serum sample of the matched case,
and the 2nd sample of controls was matched with 2nd sample of
matched case). While we controlled for all of the matched characteris-
tics in the models, the number of serum specimens differed between
cases and controls. However, because the number of specimens for
each group had to be the same to be included in the models, we used
imputation. If controls had fewer specimens than their matched cases,
we randomly selected existing control samples with replacement to
complete thematch and assignedweights to the entire set of specimens
for these controls. Theweight was calculated by dividing the number of
serum samples of a control by the number of samples of its matched
case and assigned to each control sample. The entire set of specimens
which included imputed samples was arranged by sample collection
time. All IgG values for existing and imputed serum specimens were
included in the models adapted to incorporate multiple observations
per person. The standard error was adjusted by the ratio of the gen-
erated sample size and actual sample size. Univariate and multivari-
ate analyses were used to select agents. Conditional logistic models
were used to examine the associations of agent-specific IgG antibody
levels with schizophrenia. The associations were evaluated between
schizophrenia and single/multiple agents as well as their interactions
using the GNO method (Li and Niebuhr, 2011), which is composed of
the following steps:
1. Finding the plane best separating cases and controls in a high-
dimensional space. The normal vector of the plane is defined as
gradient.
2. Finding the plane worst at separating cases and controls in a high-
dimensional space, the normal vector of which is defined as noise.
3. Finding other vectors, which are orthogonal to each other as well as
to the gradient and noise.
4. Usually, only the gradient reaches significance in distinguishing cases
from controls.
5. Removing the agents with small absolute gradient coefficients, and
therefore, contributing to a conversion from a high-dimensional to
a low-dimensional regression.
We controlled for time from serum specimen collection to diag-
nosis either continuously or categorically. The overall effect of
IgG immune response to selected infectious and food antigens on
consequential development or manifestation of schizophrenia was
reported.
The proportional hazard model in SAS 9.3 was used to perform the
conditional logistic regression. The measure of association between an-
tibody levels and schizophrenia was the hazard ratio (HR) presented
with the 95 percent confidence interval (95% CI).
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4. Results
We tested a total of 6106 serumsamples from855 caseswith schizo-
phrenia and 1165 controls. As shown in (Table 1), the majority of cases
were men, white, younger than 25 and had less than 3 years of service.
Fewer than 3% of the cases had only one serum specimen available,
about 30% had two or three, and approximately 40% had four or more
specimens. About 90% of the pre-onset specimenswere collectedwithin
4 years before diagnosis and 96% of the post-onset specimens were
collected within 2 years after diagnosis.
Each of the seven agents was fit independently to a conditional
logistic model controlling for gender, race, age and time to diagnosis
(see Table 2). Independently, no individual agent except for CMV
had major influence on the risk of schizophrenia. Our data show that
study participants with higher cytomegalovirus (CMV) IgG antibody
levels had a reduced risk of developing schizophrenia (HR= 0.90;
p = 0.02). Higher antibody levels to casein were borderline significant
in the prediction of schizophrenia with a hazard ratio of 1.08
(p= 0.06). The other agents selected for this study, gliadin, T. gondii,
vaccinia, measles and HHV-6, showed no significant independent
associations with schizophrenia.
Upon further exploration, it was determined that several agents had
significant interactions capable of altering the risk of schizophrenia.
Though, independently, an increase in casein antibody levels resulted
in just a minor elevation in the risk of schizophrenia and vaccinia
antibody levels did not differ between cases and controls, a simulta-
neous increase in the levels of antibodies to both casein and vaccinia
was associated with a corresponding and dramatic increase in the risk
of developing schizophrenia (see Fig. 1A). Similarly, Fig. 1B shows the
joint effect of measles and CMV. Table 3 details the parameter estimates
and p-values for these and other interactions that were included in the
final model. Though no four-way interaction terms were significant a
three-way interaction of measles, CMV and vaccinia had a p-value of
0.04. Thus, all subsets of two-way interaction terms were included in
the final model. Additionally, the two-way interaction of casein and
T. gondii had a p-value of 0.15whichwas deemed low enough for accep-
tance into the final model. Thus, five agents casein, measles, CMV,
vaccinia and T. gondiiwere kept in the final model.
By using the 3-way interactionmodel, we estimated an effect of sev-
eral combinations of the 2 standarddeviation increase in antibody levels
of selected infectious and food antigens on the risk of schizophrenia
(Table 4). The subjects with 2 standard deviation simultaneous
increases in antibody levels to casein, CMV, T. gondii and vaccinia had
almost 34% elevated risk of developing schizophrenia. A 2 standard
deviation increase of antibody levels to casein, measles, CMV and
vaccinia was associated with a corresponding 30% increase in the risk
of developing schizophrenia (HR= 1.30). The individual associations
of antibody levels to these infectious and food antigens and schizophre-
nia were nonexistent or barely significant.
5. Discussion
In this study, we found that schizophrenia cases had significantly
lower CMV IgG antibody levels compared tomatched controls. A combi-
nation of genetic and environmental factors resulting in some immune
dysregulation in general and the lack of the CMV IgG antibodies in par-
ticular could be themost plausible speculations.While there are no spe-
cific research results supporting this finding in existing literature, the
activation of the immune system and prolonged neuroinflammation
are well established phenomena implicated in the etiopathogenesis
and symptomatology of schizophrenia (Lin et al., 1998; Nikkila et al.,
1999; Kim et al., 2000; Theodoropoulou et al., 2001; Ebrinc et al.,
2002; Patterson, 2002; Zhang et al., 2002; Garver et al., 2003; Zhang
et al., 2004; Coelho et al., 2008; Potvin et al., 2008; Doorduin et al.,
2009; Kim et al., 2009; Song et al., 2009; Drexhage et al., 2010;
Romero et al., 2010; Drexhage et al., 2011; Weigelt et al., 2011;
Beumer et al., 2012; Brito-Melo et al., 2012). Other mechanisms could
also be considered. A protective effect of CMV was previously reported
in patients with multiple sclerosis (Zivadinov et al., 2006; Pirko et al.,
2012). Although an autoimmune nature of schizophrenia has not been
determined (Schattner et al., 1996; Goldsmith and Rogers, 2008), re-
sults of some studies are suggestive of the possibility that autoimmune
components play a role in etiopathogenic pathways leading to schizo-
phrenia, at least in some subgroups of subjects (Eaton et al., 2006;
Goldsmith and Rogers, 2008; Eaton et al., 2010; Chen et al., 2012). Be-
cause CMV has an immunosuppressive effect (Rubin, 1989; Zivadinov
et al., 2006; Varani et al., 2009), it might ameliorate the autoimmune
damage and consequently decrease the likelihood of developing schizo-
phrenia in vulnerable individuals with autoimmune reactions, which
are potentially implicated in the etiopathophysiology of schizophrenia.
Thus those who have the same vulnerabilities for developing schizo-
phrenia and did not encounter CMV are potentially more prone to
become cases. Whether or not autoimmune components are present
in schizophrenia, CMV was also reported to contribute to a decrease in
CD4+ cells and/or their activation (Sedmak et al., 1995; Heise et al.,
1998; Essa et al., 2002; Zivadinov et al., 2006; Pirko et al., 2012),
which produce proinflammatory cytokines to include TNF-α. The
TNF-α can signal through the endothelial cells to alter the tight junction
structure, leading to the increased permeability of the blood–brain bar-
rier and changed brain structure and function (Sharief and Hentges,
1991; Zeni et al., 2007).
No other changes in IgG levels to a single antigen were significantly
associated with the subsequent onset of schizophrenia. Although
Table 1
Description of schizophrenia study cases and controls.
Characteristic Level Cases Controls
n % n %
Gender Female 155 18.1 465 39.9
Male 700 81.9 700 60.1
Race Black 310 36.3 462 39.7
White 471 55.1 619 53.1
Other 74 8.7 84 7.2
Age categories 18–21 255 29.8 333 28.6
22–26 320 37.4 422 36.2
≥27 280 32.8 410 35.2
Time in servicea ≤1 171 20.0 166 14.2
N1 to ≤3 306 35.8 419 36.0
N3 to ≤5 133 15.6 200 17.2
N5 to ≤10 146 17.1 234 20.1
N10 99 11.6 146 12.5
Number of serum
draws per subject
1 22 2.6 106 9.1
2 252 29.5 414 35.5
3 225 26.3 327 28.1
4 174 20.4 318 27.3
≥5 182 21.3 0 0.0
a Time in years to case diagnosis.
Table 2
Single-agent antibody level associations with schizophrenia.
Agent modeleda Hazard ratio 95% CI p-Value
Lower Upper
Casein 1.08 1.00 1.17 0.06
Gliadin 1.05 0.97 1.13 0.26
T. gondii 1.04 0.97 1.12 0.27
CMV 0.90 0.83 0.99 0.02
Vacciniab 0.98 0.90 1.07 0.63
Measles 1.05 0.97 1.14 0.25
HHV6 1.03 0.95 1.11 0.54
Abbreviations: CMV= cytomegalovirus, HHV6= human herpesvirus type 6.
a Conditional logistic model was used for each individual agent antibody level controlling
for gender, race, age and time to diagnosis.
b 378 out of a total of 751 vaccinia IgG positive subjects had documentation of
smallpox vaccination (http://www.vaccines.mil/Smallpox). Presumably the rest were
either vaccinated outside of the military or exposed to a wild type.
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numerous research reports, including our pilot study, found an associa-
tion between T. gondii and schizophrenia (Mortensen et al., 2007;
Torrey et al., 2007; Niebuhr et al., 2008a; Pedersen et al., 2011; Wang
et al., 2013), a few others lack positive findings (Buka et al., 2001;
Conejero-Goldberg et al., 2003; Leweke et al., 2004; Xiao et al., 2009;
Yolken et al., 2011). Similar inconsistency is observed with other agents
under consideration (Albrecht et al., 1980; Shrikhande et al., 1985;
Gordon et al., 1996; Fukuda et al., 1999; Niebuhr et al., 2008b;
Dickerson et al., 2010a, 2010b; Niebuhr et al., 2011; Jin et al., 2012).
Such various findings in the literaturemight be due to themultifactorial
genetic and environmental impacts leading to schizophrenia, its
etiopathogenic and clinical heterogeneity, as well as the absence of
laboratory methods that can be used to confirm a categorically defined
diagnosis.
We also determined that agent selection by the gradient vector can
be a method of choice in high-dimensional regressions. The gradient
vector identifies the most predictive combination of the individual
agents. In fact, the increase in IgG antibody levels to several combina-
tions of agents to include casein, measles, CMV, T. gondii and vaccinia
was predictive of an 18–34% increase in the risk of developing schizo-
phrenia. Including multiple agents in the model shows that even
when a single agent may have a weak association with schizophrenia,
multiple agents may interact to increase the risk. In practice, however,
it would be very challenging to find a substantial number of subjects
with a simultaneous change in IgG antibody levels to all aforementioned
agents as the likelihood of this event is quite low. In fact, only 1% of
subjects had simultaneously above-average antibody levels to casein,
vaccinia, T. gondii and CMV. Because antibody levels with a normal dis-
tribution typically have a range covering six standard deviations, it
might be useful to categorize the population into three groups using
the tertiles of their IgG levels towards the selected agents.While bottom
and middle tertiles would include subjects with low to moderate IgG
antibody levels to these agents, the top tertile could contain those
with high IgG levels to multiple agents, which in turn might be
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Fig. 1. Hazard ratio as a bivariate function of standard value in casein and vaccinia antibody levels (A) and in CMV and measles antibody levels (B).
Table 3
The multiple agent antibody level association with schizophrenia including interaction
terms (from the GNO analysis).
Agents Parameter estimate Standard error p-Value
Casein 0.07 0.04 0.11
Measles 0.06 0.04 0.20
CMV −0.08 0.04 0.06
Measles ∗ CMV 0.12 0.07 0.11
Vaccinia −0.05 0.05 0.28
Measles ∗ vaccinia 0.05 0.06 0.49
CMV ∗ vaccinia 0.15 0.09 0.08
Measles ∗ CMV ∗ vaccinia −0.27 0.13 0.04
Casein ∗ vaccinia 0.17 0.07 0.01
T. gondii 0.03 0.04 0.40
Casein ∗ T. gondii −0.12 0.08 0.15
Abbreviations: CMV= cytomegalovirus, GNO= gradient noise orthogonal.
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indicative of a higher risk of developing schizophrenia. Although
modest, the increased risk of schizophrenia associated with exposure
to these antigens is relatively large compared with other risk factors
such as common genetic polymorphisms.
In our study, antibodies to a single infectious or food antigen were
not associated with an increased risk of developing schizophrenia.
Certain patterns of antibodies involving some but not other agents
were predictive of schizophrenia, with the magnitude of association
increasing with the level of antibodies to two or more agents. A height-
ened antibody response to a combination of several infectious and food
antigens might be an indicator of altered immune reaction rather than
an implication of any particular agent.
There are several possible ways that immune response as measured
by antibody levels could be involved in the etiopathogenesis of schizo-
phrenia. First, a persistent low grade inflammation accompanying a
response to a certain combination of infectious and food antigens in in-
dividuals with genetic predisposition to schizophreniamight contribute
to the risk of developing schizophrenia. In this situation, the chronic
inflammation would be considered an independent environmental
risk factor. Alternatively, the same genetic variation(s) could be inde-
pendently responsible for both schizophrenia and alterations of im-
mune regulation, in which case accompanying inflammation might
not be directly associated with schizophrenia etiopathogenesis but
rather a comorbid condition. Yet another possible scenario is when
the same and/or different genetic variations might contribute to both
schizophrenia and heightened immune reaction resulting in chronic in-
flammation. In this case, the chronic inflammationwould be considered
a consequence of gene–environmental interaction and could have an
additive ormultiplicative effect to other genetically determinedmecha-
nisms leading to schizophrenia. It is of note that the antibody levels
we measured could not be attributed to anti-psychotic medications or
other epiphenomena related to the diagnosis and treatment of schizo-
phrenia since they were present prior to disease diagnosis.
This study has some notable strength as well as some limitations.
Strengths of this study include the follow-up of an initially disease-
free population with subsequent complete and reliable case/control
ascertainment (Millikan et al., 2007). Due to the large available control
population, we also were successful in matching on a number of vari-
ables to control for potential confounding. Collecting multiple serum
specimens years before disease onset also provides a more reliable
and longitudinal assessment of a subject's IgG levels. Because we did
not detect inverse correlations between specimens' age and IgG anti-
body levels, the length of the specimen storage should not be a source
of non-differential bias. In addition, case and control serum specimens
were matched on the time of collection and the length of storage, so
we do not expect our results to be differentially biased or confounded.
This study population was composed mostly of young adults
(18–40) who were screened medically and cognitively before entering
military service and, therefore, may not be generalizable to other popu-
lations. In addition, this study considered only seven infectious and food
antigens preselected based on prior studies for possible associationwith
schizophrenia. Additional agents should be the focus of future studies.
Also, some cases had more serum specimens retrieved from the
DoDSR than their controls. It was financially prohibitive to have as
many specimens per control as per case and from a study power per-
spective, not prudent to have as few specimens per case as per control,
so this limitation was addressed statistically. Furthermore, no genetic
information was available on the subjects. A future study could benefit
from this information by attempting to interconnect various environ-
mental and genetic factors.
It is of note that the associations we found between antibodies were
complex, requiring multiple samplings for identification. Our findings
reinforce the notion that the etiology and pathogenesis of schizophrenia
are very complex and depend on multiple environmental and genetic
factors which may be mediated by non-specific changes in immune
system reactions. Our results are consistent with the growing body of
literature indicating that schizophrenia is likely to involve multiple eti-
ologies and biological pathways. The importance of performing longitu-
dinal investigations of biologically relevant markers in complex brain
disorders such as schizophrenia is hard to overestimate.
Future studies should focus on the potential gene–environment
interaction as well as nonlinear effects. Such studies should also be lon-
gitudinal and allow for analysis of genetic markers as well as pre-onset
serum infectious, inflammatory and environmental biomarkers inde-
pendently and interactively. The successful conclusion of such studies
will contribute to the understanding of the causal pathway and poten-
tially the early diagnosis, treatment and prevention of this devastating
disease.
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Table 4
Hazard ratios (HRs) for risk of schizophrenia per two standard deviation increase in combined agents antibody levels with different permutationsa.
Casein Measles CMV T. gondii Vaccinia Parameter Standard error Hazard ratio 95% CI
Lower Upper
1 0 1 1 1 0.29 0.13 1.34 1.03 1.75
1 1 1 0 1 0.26 0.06 1.30 1.15 1.47
1 1 1 0 0 0.24 0.04 1.27 1.17 1.38
0 1 1 1 1 0.19 0.21 1.21 0.80 1.83
0 1 1 1 1 0.19 0.21 1.21 0.80 1.83
0 1 0 1 1 0.17 0.09 1.19 1.00 1.40
0 0 0 1 1 0.17 0.08 1.18 1.02 1.38
1 0 0 1 1 0.16 0.06 1.18 1.04 1.33
a 1 = agent included in the model, 0 = agent excluded from the model.
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